Würzburger Str. 1, 97941 Tauberbischofsheim, Germany

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation

BIOCARD Study

An in-person initial visit is required. Annual Follow-up visits can be conducted in person or over the phone.

Diverse VCID "Vascular Cognitive Impairment and Dementia"

The study will require 3 visits: • A baseline visit, plus 2 subsequent annual follow-up visits over 3 years • The follow-up visits may be spaced up to 18 months apart. Participation in this study will involve completing physical, neurological, and cognitive examinations sufficient to complete the Alzheimer’s Disease Program Uniform Data Set (UDS), blood draws, and a brain MRI at baseline, and at annual follow-up visits 2 and 3. The de-identified data collected from the study will be shared with members of the Diverse VCID Consortium and other collaborating researchers for the study of vascular health and other conditions (e.g., Alzheimer’s disease, other forms of dementia, mental illness, HIV/AIDS, cancer, heart disease, and others). Recruitment into the study ends in March of 2024 and the final study will be concluded August 30, 2027.

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - (FIGHT-302)

For more information, please contact Incyte Corporation at 1.855.463.3463 or visit **[www.incyteclinicaltrials.com](https://www.incyteclinicaltrials.com/)**

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)

Interactive Effects of Periodontitis, the Gut Microbiome, and ApoE4 in Alzheimer’s Disease

Study schedule: In total, there will be 4-5 study visits over six weeks. -You will have a medical exam. -You will have dental exam. -You will give a saliva sample. -You will give a stool sample. -You will give a blood sample. -You will complete a cognitive assessment.

Phase 1/2 Study Of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Patients With Follicular Non-Hodgkin’s Lymphoma

See CT.gov: **[**www.clinicaltrials.gov/ct2/show/NCT02501473**](https://www.clinicaltrials.gov/ct2/show/NCT02501473?term=G142&rank=1)**

A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease (Hibiscus Study)

FT-4202 is designed to activate PKR and thereby modulate RBC metabolism by impacting two critical pathways in RBCs. The FT-4202 clinical development program will investigate whether decreasing 2,3-DPG may help oxygen bind to hemoglobin (i.e. increasing oxygen affinity), and thereby increase ATP and impact RBC function. This study is a randomized, placebo-controlled, double-blind, multicenter Phase 2/3 study of patients age 12 to 65 years (inclusive), with sickle cell disease. There are two planned interim analyses in this study design. Initially, patients will be randomized at 1:1:1 to one of two dose levels of FT-4202 or placebo. At the first interim analysis, one of the two FT-4202 dose levels will be selected for the Phase 3 portion of the study, in which patients will be randomized at 1:1 to the selected FT-4202 dose or placebo. Efficacy on hemoglobin will be evaluated at the second interim analysis, and then will be tested along with evaluation of efficacy on vaso-occlusive crises at the final analysis. Following completion of 52 weeks of double-blind treatment, patients may enter a 52-week FT-4202 open-label extension period. **For more information, please visit[ _hibiscusstudy.com_](https://hibiscusstudy.com/?utm_source=CenterWatch&utm_medium=Listing&utm_campaign=Hibiscus).**